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Abstract
A number of agents are now available for empirical antifungal treatment (EAFT) of patients with persistent fever and neutropenia.
We carried out a study of efﬁcacy of antifungal drugs to prevent breakthrough invasive aspergillosis by reviewing the medical
records of all consecutive patients who received EAFT from November 2005 to February 2006. Patients’ characteristics and the
type, dose and duration of antifungal therapy were recorded. Breakthrough invasive fungal infections were documented according
to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) deﬁnition. Fifty-six episodes of persistent
fever with neutropenia requiring EAFT were recorded among 49 patients. All patients received high-dose chemotherapy for acute
myeloid leukaemia (51%), acute lymphoid leukaemia (12%), lymphoma (14%) or other haematologic conditions (22%). Fourteen
(29%) and ﬁve (10%) patients were allogeneic and autologous haematopoietic stem cell transplant recipients, respectively. Caspofun-
gin was prescribed initially in 40 episodes (71%), amphotericin B (AmB) desoxycholate and liposomal AmB being prescribed in six
(10%) and ten (18%) episodes, respectively. Six patients were switched from liposomal AmB to caspofungin because of adverse
events. The median duration of antifungal therapy was 9 days. During follow-up, six patients (12%) were diagnosed with invasive
aspergillosis after a median of 8 days (range 3–16 days) of EAFT. Invasive aspergillosis breakthrough occurred in 6/46 (13%) caspo-
fungin recipients and in 0/16 (0%) AmB recipients (OR 3.1, p 0.32). The observed high rate of invasive aspergillosis among caspo-
fungin recipients requires further evaluation.
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Introduction
The role of invasive fungal infections (IFI) as the leading
cause of death in cancer patients with prolonged neutropenia
[1,2] and clinical observations showing the importance of
early treatment in the prognosis of IFI [3] have led to the
concept of empirical antifungal therapy as a treatment strat-
egy in patients with persistent fever and neutropenia. Two
small randomized trials, which did not comply with modern
methodological requirements, laid the scientiﬁc foundation
for the use of amphotericin B (AmB) desoxycholate as
empirical antifungal therapy (EAFT) in these patients [4,5].
More recently, liposomal AmB and caspofungin, but not
voriconazole, have been approved for EAFT [6–8]. The
recent availability of less toxic antifungal agents may have
facilitated the uninformed and inappropriate prescription of
these drugs, with the potential risks of insufﬁcient efﬁcacy
and selection of resistant fungal strains. Over the last few
years in our institution, there has been an increased pre-
scription of caspofungin, and a parallel decrease in prescrip-
tion of AmB. To better understand the way in which
physicians prescribe antifungal agents in patients with febrile
neutropenia, and to assess the efﬁcacy and safety of this
strategy, we undertook a prospective 3-month audit of EAFT
in our institution.
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Materials and Methods
The Saint-Louis hospital is a 650-bed tertiary hospital with
major clinical activities in haematology and oncology. The
present study was carried out by reviewing the medical
records of all consecutive patients admitted to the haematol-
ogy, oncology, intensive care unit and infectious diseases
wards and treated with EAFT between 7 November 2005
and 7 February 2006.
EAFT was deﬁned as the use of antifungal agents in
patients with neutropenia and persistent or recurrent fever
despite broad spectrum antibiotics, and without clinical or
radiological signs of IFI. Neutropenia was deﬁned by an abso-
lute neutrophil count <500/mm3 or <1000/mm3 but was
expected to drop <500/mm3 within 48 h. Patients with total
leucocyte count <1000/mm3 after chemotherapy and without
a neutrophil count available, were also considered to fulﬁll
the deﬁnition of neutropenia.
Fever was deﬁned as a temperature ‡38C over 1 h or
‡38.3C once. Voriconazole, caspofungin and liposomal AmB
were delivered by the central pharmacy of our institution
using restrictive nominative formularies but AmB desoxycho-
late was not.
Pharmacists were asked to identify all orders for EAFT
from their records. Nurses were asked about any new pre-
scription of unrestricted AmB desoxycholate each week.
One infectious diseases specialist and one pharmacist, both
members of the Infectious Diseases Intervention Unit, col-
lected information from each treated patient chart and ana-
lyzed the data once the antifungal drug had been stopped
aiming to avoid interfering with the prescription. The data
recorded were: demographic characteristics, date and ward
of admission, underlying disease, type of chemotherapy and
antimicrobial therapy, presence of fever, leucocyte and abso-
lute neutrophil count, serum creatinine level, concomitant
use of nephrotoxic agents at the initiation of the EAFT, cur-
rent or prior (co)administration of antifungal drugs
(3 months before EAFT initiation), resolution of fever under
antifungal treatment, breakthrough IFI and mortality. A
breakthrough IFI wad deﬁned as any IFI diagnosed after
‡3 days of EAFT, as proposed in a study by Walsh et al. [7]
comparing caspofungin and liposomal AmB in patients with
persistent fever and neutropenia. Galactomann blood index
(threshold 0.5, enzyme-linked immunosorbent assay, Ag
Aspergillus; Bio-Rad. Hercules, CA, USA) was measured
once a week in the bone marrow transplantation unit and
chest computed tomography (CT) was performed before the
transplantation. No routine diagnostic procedure was per-
formed in other units unless an IFI was suspected.
If information was missing in the medical, laboratory and/
or nurse charts, the medical team was interviewed to collect
the missing data. Pharmacology parameters were also
recorded regarding the doses, intervals between administra-
tion and length of treatment for each antifungal agent. If a
patient was treated for two or more distinct episodes of
fever and neutropenia during the 3-month study period, each
episode was analyzed independently.
Results
Overall, 56 EAFT episodes among 49 patients were retained
for analysis (seven patients had two separate febrile neutro-
penia episodes).
Forty-four patients were male (90%) and the median age
was 41 years (range 15–76 years). Forty-ﬁve patients (92%)
were hospitalized in the haematology or oncology unit, four
in the intensive care unit. Thirty-one patients (63%) were
treated for acute leukaemia (25 acute myeloid leukaemia and
six acute lymphoid leukaemia), seven (14%) for lymphoma
and 11 (22%) for other haematologic conditions. Fourteen
patients (29%) were allogeneic haematopoietic stem cell
transplant (HSCT) recipients and ﬁve (10%) had undergone
an autologous stem cell transplant. Antifungal prophylaxis
(oral ﬂuconazole in all cases) was prescribed in 23 patients
(47%) after the administration of chemotherapy and before
the beginning of the EAFT.
EAFT was started because of persistent fever despite
broad-spectrum antibiotics (22 episodes, median duration of
fever 7 days), recurrence of fever after transient apyrexia
under antibiotics (27 episodes), clinical signs of sepsis with
temperature <38C (three episodes) and tachycardia and
elevated C reactive protein (two episodes).
A profound neutropenia (as deﬁned as an absolute neutro-
phil count <100/mm3) was noted in 23 episodes (41%). The
median duration of chemotherapy-induced neutropenia was
28 days (range 1–61 days). EAFT was started after a median
duration of neutropenia of 13 days (range 1–58 days).
First-line EAFT was caspofungin in 40 episodes (71%),
AmB desoxycholate in six cases (11%) and liposomal AmB in
ten cases (18%) (Fig. 1). In six episodes, liposomal AmB was
switched to caspofungin for drug-related adverse events
(renal insufﬁciency in four, infusion related chills in two). The
median duration of EAFT was 9 days. Reasons for discon-
tinuing EAFT were full neutrophil count recovery in 43
(77%) episodes, a suspected IFI as a result of Aspergillus in
eight episodes (14%) (of which two were later not con-
ﬁrmed), patients discharged from hospital in two episodes
(9%), and death in three episodes (5%). The doses and fre-
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quencies of administration of antifungal agents were in agree-
ment with current recommendations.
Eight suspicions of breakthrough invasive aspergillosis (IA)
led to the interruption of the EAFT. In two patients, the
diagnosis of IA was eventually not conﬁrmed (false-positive
Aspergillus galactomannan antigenemia as a result of tazocillin
in one patient, contaminated blood culture with Aspergil-
lus sp. in one patient). The diagnosis of IA was retained in
six treated patients during the course of the EAFT (11% of
episodes), after a median of 8 days (range 3–16 days) after
EAFT initiation (Table 1). The site of infection was the lungs
in all cases. Two patients had received prophylactic treat-
ment with oral ﬂuconazole (400 mg od) before EAFT. All
patients had new inﬁltrates on chest X-ray. According to the
2008-revised European Organization for Research and Treat-
ment of Cancer (EORTC) classiﬁcation, there were three
patients with possible IA and three with probable IA [9]. All
patients then received voriconazole (together with caspofun-
gin in one case). At the time that breakthrough IA was diag-
nosed, all patients were on caspofungin EAFT. IA emerged
during six out of 46 episodes with caspofungin EAFT (13%)
compared to none out of 16 episodes with AmB EAFT (des-
oxycholate and liposomal) (OR 3.1; median unbiased exact
estimate, with 95% CI 0.42 to inﬁnity, p 0.32 by Fisher’s
exact test).
No invasive fungal infection due to Candida or other fungi
was reported throughout the study. Outcome review at the
last study point (median 18 weeks after the study period)
revealed that 14 patients died (28%) but only one death was
related to IA.
Discussion
Fungal infections were recognized some decades ago as
potential causes of persistent or recurrent fever in patients
receiving antibiotics during an episode of neutropenia [1,4,5].
Various studies have demonstrated that patients with acute
leukaemia and allogeneic HSCT recipients are at high risk of
IFI as a result of prolonged and profound neutropenia and/or
immunosuppression for graft-versus-host disease [10,11].
Most patients in the present study belonged to one or both
of these conditions (acute leukaemia 63%, haematopoietic
cell transplantation 29%) and were therefore at high risk of
developing an IFI during episodes of febrile neutropenia. In
addition, the median duration of chemotherapy-induced
neutropenia among our patients was long (28 days, range
1–61 days) and neutropenia was severe, with an absolute
neutrophil count <100/mm3 in 41% of episodes; EAFT was
started after a median duration of neutropenia of 13 days.
The present study thus involved a much higher risk group of
patients than those included in most other EAFT studies,
which could explain the high incidence of breakthrough IA
reported here.
The results obtained in the present study show that
caspofungin was the preferred ﬁrst-line EAFT at our institu-
Caspofungin
n = 40 n = 6*
Liposomal
amphotericin B
n = 10
Amphotericin B
desoxycholate
n = 6
56 episodes of febrile 
neutropenia in 49 adults
receiving EAFT
Invasive
aspergillosis
n = 6 
Full
neutrophil
recovery
n = 43
Death
n = 3
Discontinuation
of EAFT for
other reasons
n = 4**
FIG. 1 Empirical antifungal therapies
(EAFT) and outcome during 56 episodes
of febrile neutropenia after chemother-
apy among 49 patients. *Switch from
liposomal amphotericin B (AmB) to ca-
spofungin (n = 6) because of toxicity
(renal insufﬁciency, n = 4) or side effects
(infusion related chills, n = 2). **Sus-
pected invasive aspergillosis (n = 2),
hospital discharge (n = 2).
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tion because, overall, it was used in 41% of febrile neutrope-
nic episodes, which is a much higher rate than in other Euro-
pean centers [12].
This wide use of caspofungin is likely a result of its favour-
able safety proﬁle, especially its renal safety [7]. Indeed, in
the present study, liposomal AmB was switched to caspofun-
gin in six out of ten episodes because of renal toxicity. The
high rate of renal toxicity with liposomal AmB compared to
the studies conducted by Walsh et al. [7,8,13] was probably
related to the use of this drug with other nephrotoxic agents
in HSCT recipients.
No invasive Candida infection was found in the present
study, which differs from the results of other large trials that
have reported breakthrough invasive infections as a result of
Candida in 0.5–3.5% of patients [7,8,13]. This discrepancy can
be explained, in part, by the small size of the present study
and the use of prophylactic ﬂuconazole in 47% of our
patients before EAFT.
The second important observation made in the present
study is the very high rate of breakthrough IA (11%) among
patients receiving EAFT. Although IA cases were only proba-
ble or possible according to the EORTC/Invasive Fungal
Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (MSG)
deﬁnition, this rate of IA is much higher than that reported
in recent comparative trials among patients receiving EAFT
(<1–3% of patients) [7,8,13–16]. One possible explanation
for this difference is the high-risk patient population involved
in the present study. Indeed, subgroup analysis of patients at
high risk in randomized trials have yielded IFI rates of up to
9.2% with liposomal AmB but only 1.4% with voriconazole
[8]. A subgroup analysis of patients with acute myeloid leu-
kaemia treated empirically with liposomal AmB or caspofun-
gin, also yielded a breakthrough IFI rate of 7% in the
caspofungin group and 5% in the liposomal AmB group [7].
These data also suggest that not all antifungal agents may
have the same efﬁcacy in preventing breakthrough IFIs, with
better results being obtained with voriconazole and poten-
tially worse results with caspofungin. Caspofungin is only fun-
gistatic against Aspergillus in vitro, whereas voriconazole and
liposomal AmB are fungicidal, and this might translate into
lower clinical efﬁcacy [17].
We were surprised to see all breakthrough IA cases
occurring when patients were receiving EAFT with caspofun-
TABLE 1. Invasive aspergillosis (IA) in patients treated with empirical antifungal therapy (EAFT) during febrile neutropenia
Age
(years)
Underlying
disease
Duration of
neutropenia
before IA
diagnosis
(days)
EAFT: drug(s)
and duration
before IA
diagnosis
Classiﬁcation
of IA
Criteria for
diagnosis Chest CT scan signs Microbiology
61 ALL 23 Caspofungin,
3 days
Probable CT scan,
GI-BAL+
Upper right lobar nodule,
size 25 mm, surrounded
by ground-glass
attenuation
GI-BAL: 6.83
GI-B/week: all negative
BAL, tracheal aspiration
and sputum negative for
Aspergillus or other
pathogens
60 AML 62 Caspofungin,
9 days
Possible Clinical signs,
CT scan
Bilateral disseminated
nodules, size 10 mm,
surrounded by ground-
glass attenuation
GI-B/week: all negative
43 Fanconi anemia,
Allogeneic
HSCT
94 Liposomal
amphotericin B,
3 days then
caspofungin,
16 days
Probable Clinical signs,
CT scan, GI-B+
Bilateral micro nodules
and areas of ground-
glass inﬁltrates
GI-BAL: 5
GI-B: 1.22 increasing to 4.01
BAL, tracheal aspiration
and sputum negative for
Aspergillus or other
pathogens
48 AML 25 Amphotericin B
10 days, then
caspofungin,
9 days
Possible Clinical signs,
CT scan
Bilateral disseminated
nodules, size up to
25 mm and areas
ground-glass inﬁltrates
GI-B/week: all negative
GI-BAL: negative
BAL, tracheal aspiration
negative for Aspergillus
or other pathogens
21 Severe aplastic
anemia Allogeneic
HSCT
28 Caspofungin,
7 days
Probable Clinical signs,
CT scan, GI-B+,
GI-BAL+, culture
Nodules with halo sign GI-BAL: 6.83
GI-B/week: all negative
Sputum culture positive
for Aspergillus fumigatus
BAL, tracheal aspiration
negative for Aspergillus
or other pathogens
58 AML 19 Caspofungin,
3 days
Possible CT scan signs Bilateral disseminated
nodules, size 25–40 mm,
surrounded with ground-
glass inﬁltrates
GI-B/week: all negative
BAL, tracheal aspiration
negative for Aspergillus
or other pathogens
AML, acute myeloı¨d leukaemia; ALL, acute lymphoı¨d leukaemia; CT, computed tomography; HSCT, haematopoietic stem cell transplant; GI, galactomannan index; GI-B, GI in
blood; GI-B+, two consecutive GI-B? 0.5 in blood; BAL, bronchoalveolar lavage; GI-BAL, GI in BAL; GI-BAL+, GI-BAL? 0.5.
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gin. Six cases were reported among 46 episodes treated with
caspofungin compared to none among 16 patients treated
with AmB. Although this difference was not signiﬁcant, there
was a trend towards a lower efﬁcacy of caspofungin in pre-
venting breakthrough IA in the present study. Several limita-
tions might have contributed to this observation. First, the
study was underpowered to show signiﬁcant differences
because of its small sampling size and short duration. Second,
in the present study, we cannot exclude the possibility that
patients being treated empirically with caspofungin were at
higher risk of developing an IFI. Third, it is possible that
some of IA was present at the start of EAFT but overlooked.
Indeed, baseline invasive fungal infections have been reported
in up to 5% of patients by Walsh et al. [7] and our patients
did not undergo a chest CT scan at the start of EAFT. How-
ever, neither clinical, nor chest X-ray signs were noted in
the patients charts before the diagnosis of IA, and surveil-
lance with galactomannan assay is standard practice in our
centre. Also, in the present study, we only considered IA
diagnosed ‡3 days after starting EAFT, as suggested by
Walsh et al. [7]. Interestingly, a recent study mentioned the
occurrence of IA in nine high-risk patients (HSCT recipients)
treated empirically with caspofungin, with Aspergillus isolates
exhibiting high MIC to caspofungin in two cases [18].
Because caspofungin will be widely used as EAFT, these
observations require further evaluation.
Nevertheless, caspofungin has been successfully used as
salvage therapy for IA [19] and encouraging results have
been reported in patients receiving chemotherapy or under-
going solid organ transplantation [20]. The experience with
caspofungin as ﬁrst-line therapy for IA has also been
reported in two prospective trials with favourable response
rates of 33% among patients with acute leukaemia and alloge-
neic HSCT recipients [21,22].
In conclusion, despite its limitations. the present study
found a high rate of breakthrough IA among high-risk
patients receiving caspofungin as EAFT, which is now widely
used because of its favourable safety proﬁle. Additional stud-
ies are required to conﬁrm these results.
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